SAPAM - Sustainable Access Platform for Affordable Medicines & Devices
SAPAM initiated as a support program for the SADC Pharmaceutical Business Plan in 2009, and now continues to operate regionally through engagement with various partners and facilitators in the public and private sectors.
Our experience, core skills and institutional memory brings an armamentarium that is designed to establish sustainable solutions.
Innovatively provide essential solutions, products and support that improves access to healthcare services and delivery, for all.
Areas of Operation
SAPAM focusses on Health Systems Strengthening (HSS) with emphasis on improving access challenges to essential medicines, devices and health commodities. We contribute to the WHO defined six building blocks of health systems functions as follows:
- Essential Medicines and Health Commodities – encouraging procurement cooperation among countries with the aim of effecting cost savings and improving access to essential medicines and devices in their regions
- Service Delivery – by supporting and providing technical assistance to National Medicines Procurement Agencies (NMPAs) in Pharmaceutical Procurement Supply Management (PPSM) standards and good practices
- Information and Technology – development of information and price sharing medicines databases for information and work sharing of medicines prices, registration status, manufacturers and suppliers among the countries to improve access, quality, and affordability, custom built IoMT (Internet of Medical Things) solutions and applications
- Human Resources – capacity building in procurement and supply management of essential medicines and related commodities
- Governance – working with Civil Society organisations to encourage transparency through provision of accurate, relevant data on availability and prices of medicines which are discussed with responsible Government departments with the aim of implementing interventions and instituting corrective actions
- Finance – research and identification of areas of potential cost savings to improve access and affordability of medicines to countries in the regions
